Welcome to our dedicated page for Opthea SEC filings (Ticker: CKDXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Opthea Limited (CKDXF) provides access to the company’s U.S. regulatory documents as a foreign issuer. Opthea files Form 6-K current reports under the Securities Exchange Act of 1934 and identifies itself as a Form 20-F filer, meaning it follows the foreign private issuer reporting framework. These filings often attach press releases as exhibits and may be incorporated by reference into existing registration statements, such as a Form S-8.
Investors can review Form 6-K reports that cover topics including a press release on Opthea’s intention to voluntarily delist its American Depositary Shares from The Nasdaq Global Select Market, a press release on quarterly report and cashflow information, 2025 annual general meeting results, and the appointment of a company secretary. Some of these 6-Ks explicitly state that the attached press releases are incorporated by reference into a Form S-8 registration statement, which is relevant for understanding how Opthea updates its disclosure documents.
A key document on this page is Opthea’s Form 25 dated November 10, 2025. This filing is a Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act for the company’s American Depositary Shares, each representing eight ordinary shares with no par value. The Form 25 indicates that Opthea relied on Rule 12d2-2(c) for voluntary withdrawal of the ADSs from listing and registration on The Nasdaq Global Select Market and notes that, as of the filing date, the company did not have an audit committee meeting Nasdaq Listing Rule 5605(c)(2) composition requirements.
Through this page, users can follow the sequence of Opthea’s filings related to its ADSs, financial and cashflow reporting via press releases, AGM outcomes, and governance announcements. AI-powered tools on the platform can help summarize lengthy documents, highlight the purpose of each form, and clarify how filings such as Form 6-K, Form 20-F references, Form S-8 incorporations, and Form 25 notifications fit together in Opthea’s U.S. regulatory history.
Opthea Limited filed a Form 25 to remove its American Depositary Shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The securities are ADSs, each representing eight ordinary shares, previously listed on The Nasdaq Global Select Market. The notification was signed by Chief Executive Officer Jeremy Levin on November 10, 2025.
Opthea Limited filed a Form 6-K noting it issued a press release announcing its intention to voluntarily delist its American Depositary Shares from the Nasdaq Global Select Market.
The press release, dated October 29, 2025, is furnished as Exhibit 99.1 and is incorporated by reference into Opthea’s Form S-8 (File No. 333-251052). This notice focuses on the planned delisting of Opthea’s ADSs from Nasdaq as described in the press release.
Opthea Limited submitted a Form 6-K as a foreign private issuer, primarily to furnish a press release announcing the appointment of a new company secretary. The report lists this press release as Exhibit 99.1 and is signed on behalf of Opthea by Executive Officer Jeremy Levin.
Opthea Limited, a foreign private issuer, filed a Form 6-K for October 2025. The filing mainly furnishes a press release, listed as Exhibit 99.1, announcing that Opthea received an A$10.8 million R&D Tax Incentive, a government-related research and development benefit.
Opthea Limited (CKDXF) filed its Form 20-F describing a company without product revenues that continues development of biologic candidates including sozinibercept and OPT-302. Management disclosed that it has not obtained regulatory approval for any product candidate, has incurred significant losses, and expects to need additional capital to complete clinical development. The company may reformulate candidates to target VEGF-C/D; if reformulation is not viable directors may consider a return of capital and ceasing operations.
The report discloses a resolution of the Development Funding Agreement: DFA investors provided US$20.0 million and were issued equity equal to 9.99% fully diluted (136,661,003 ordinary shares), liens were released and the DFA terminated. As of August 30, 2025 the Group had US$19.3 million of cash and cash equivalents. Management concluded internal control over financial reporting was not effective as of June 30, 2025 due to errors in accounting for the Funding Agreement and investor options.
Opthea Limited has filed a Form 6-K as a foreign private issuer for September 2025. The filing mainly serves as a cover to provide two key documents to investors and regulators.
Exhibit 99.1 is titled “Opthea Limited Annual Report 2025,” and Exhibit 99.2 is titled “Opthea Corporate Governance Statement 2025,” indicating the company has submitted its latest annual reporting and governance information.